17 research outputs found

    Additional file 10: of SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1α axis

    No full text
    Figure S5. Representative western blots and corresponding densitograms showing that in K562 (a) and LAMA84 cells (b) curcumin decreased nuclear levels of HIF-1α. Ponceau S of nuclear extract was used as loading control. Intensities of proteins band (in Ponceau S the band used is indicated with arrow) were calculated from the peak area of densitogram by using Image J software. Ctrl: control cells. (PPTX 809 kb

    Additional file 11: of SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1Îą axis

    No full text
    Figure S6. IPO7/miRNAs correlation. a Analysis performed by using microRNA target prediction software miRSearch V3.0 showed that IPO7 is a validated target of miR-22 and miR-9. b Analysis of predicted multiple targets performed by MicroRNA Target prediction (miRTar) tool ( http://mirtar.mbc.nctu.edu.tw/human/ ) revealed within the CurcuDown-Regulated dataset the presence of several of miR-22 targets beside IPO7. No target of miR-9 was found. (PPTX 179 kb

    Additional File 12:

    No full text
    Figure S7. Anti-proliferative effects of curcumin, imatinib and curcumin+imatinib combination on CML cell viability. Curcumin and imatinib were tested for their anti-proliferative effects on K562 (a) and LAMA84 cells (b). The assays were performed by using curcumin and imatinib singly (using the reported doses) or in combination (20 μM curcumin held constant and imatinib at reported concentrations. In K562 cells combination compound treatments showed significant differences compared to single imatinib treatments for all doses tested (p < 0.001). In LAMA84 cells combination compound treatments showed significant differences compared to single imatinib treatments for lower doses tested (p < 0.001 at 0.1 and 0.2 μM), while no significant differences were observed between combination compound and imatinib at 0.5–5 μM because high cell death occurred. Combination Index (CI) analysis of growth inhibition in K562 (c) and LAMA84 cells (d) after 48 h incubation using curcumin (20 μM) and imatinib (different concentrations). Data from Fig. S6a and S6b were converted to Fraction Affected (FrAf) and plotted against Combination Index (CI). Results were as follows for imatinib concentration: ▲ = 0.1 μM; ♦ = 0.2 μM; ● = 0.5 μM; □ = 1 μM; ○ = 5 μM. Straight line on the graph designates a CI equal to 1. Combination Index interpretation was as follows: CI value of 1 indicates additivity; CI < 1 indicates synergism; and CI > 1 indicates antagonism. (PPTX 50 kb

    <i>in vitro</i> inhibition of exosome-stimulated angiogenesis by CTO.

    No full text
    <p>(a) Phase contrast micrographs showing the effects of LAMA84R exosomes and CTO treatment on endothelial network formation (matrigel assay). Few cables are observed when HUVEC are plated in low serum medium (CN). Addition to HUVEC cells of 10 ng/ml of recombinant IL8 (Rec IL8) or 50 µg/ml of LAMA84R exosomes (Exo) induces the formation of capillary-like structures. No tube formation is observed when HUVEC are plated in the presence of 50 µg/ml of exosomes plus neutralizing anti-IL8 antibody (Exo + N Ab IL8). CTO inhibits the effects of recombinant IL8 (10 µM CTO + Rec IL8) or exosomes (Exo +10 µM CTO) on tube formation by HUVEC on matrigel. (b) Histograms showing the quantitative analysis of the cables length by Image J software.</p

    Effects of CTO on cell adhesion molecules and cytokines mRNA expression.

    No full text
    <p>(I) CTO reverts the effects of CML exosome treatment on VCAM1, ICAM1 and IL8 mRNA expression in HUVEC cells. VCAM1 (a), ICAM1(b) and IL8 (c) mRNA expression increased in a dose dependent manner after adding exosomes (Exo) to endothelial cell monolayer. CTO (1-5-10 µM) reverts these effects in a time- and dose dependent manner. (II) VCAM1, ICAM1 and IL8 mRNA expression in HUVEC treated for 6 h either with low serum medium (CN), or with 50 µg/ml exosomes (Exo), or with 10 ng/ml of recombinant IL8 (Rec IL8) with or without CTO 10 µM, or with 50 µg/ml exosomes plus 10 µg/ml of a neutralizing anti-IL8 antibody (N Ab IL8). Values are representative for three independent experiments. *p≤0.05; **p≤0.01.</p

    CTO inhibits the effects of LAMA84R exosomes on HUVEC migration.

    No full text
    <p>(a) Effects on migration of CTO-treated endothelial cells using 50 µg/ml of exosomes as chemoattractant. (b) 50 µg/ml of exosomes (Exo) with or without 10 µg/ml of neutralizing anti-IL8 antibody (N Ab IL8), or 10 ng/ml of recombinant IL8 (Rec IL8) with or without neutralizing anti-IL8 antibody were added as chemoattractants to the bottom wells., Motility of endothelial cells with or without increasing doses of CTO (1–10 µM) was evaluated as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0042310#s2" target="_blank">Material and Methods</a>. *p≤0.05; **p≤0.01.</p
    corecore